Windward Bio closes IPO and private placement for $251.2 million
Windward Bio priced its IPO at $17 per share and offered underwriters an option to buy additional shares. After full exercise of that option, the company sold 11,838,234 shares and completed a concurrent $50 million private placement to Sanofi, bringing combined gross proceeds to approximately $251.2 million.
Windward Bio shares rise 67.65% after Nasdaq debut
Windward Bio shares rose 67.65% to US$28.50 in early trading after a Nasdaq listing that raised about US$175 million, followed by a US$144.2 million shelf registration tied to its employee stock ownership plan. The company had no meaningful revenue and reported a US$68.2 million net loss, while its price-to-book ratio exceeded industry and peer averages.
Windward Bio trades above biotech industry book-value average
Windward Bio rose from US$17.00 to US$28.50 in its 13 November 2026 Nasdaq debut after an IPO that raised capital for late-stage antibody programs. The stock trades at about 6.2 times book value, above the biotech industry’s roughly 1.8 times. The article notes ongoing cash outflows and clinical risk, and says future trial results and financing decisions will shape whether current expectations are justified.